Natera, Inc. (NTRA): R&D Expense
$624.11M
Year ended 2025-12-31
$787.38M
Trailing 12 months to 2026-06-30
+25.4%
3-year compound annual growth
+44.2%
5-year compound annual growth
+36.5%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $624.11M | +54.4% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $404.14M | +26.0% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $320.68M | +1.3% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $316.42M | +19.8% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $264.21M | +164.1% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $100.03M | +94.8% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $51.36M | 0.0% | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $51.35M | +2.6% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $50.06M | +19.6% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $41.86M | +51.1% | 2019-03-15, From 2016-01-01 |
| 2015-12-31 | $27.71M | +60.3% | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | $17.29M | +49.7% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $11.55M | n/a | 2016-03-24, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Natera, Inc. (NTRA) | 2025-12-31 | $624.11M | +54.4% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $364.19M | +4.7% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $101.58M | -10.8% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
Compare NTRA, GH, CAI, VCYT side by side · Screen every company in Services-Medical Laboratories ↗